Sun Pharmaceutical Industries Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sun Pharmaceutical Industries Ltd.
5 Talking Points As Sun's Cequa Hits Home Turf And There's Restasis
Cequa arrives in India, almost four years post US debut with Sun deploying what has generally been perceived as the text-book launch approach of foreign firms in the country. Scrip delves into the market dynamics in a segment where AbbVie's blockbuster Restasis is well entrenched.
10 Approvals To Look Out For In Q2
The second quarter has already seen the approval of Gamida Cell’s cell therapy Omisirge, and with the help of Biomedtracker, Scrip highlights 10 of the more interesting new drug approvals due in the next three months.
iPLEDGE REMS: US FDA Advisory Cmte. Supports Relaxing Restrictions But Wants More Data
Panel favors elimination of 19-day lockout after patients who can become pregnant miss the first prescription pickup and continuation of at-home pregnancy tests. Members call for more data from isotretinoin sponsors on why acne patients are not participating in pregnancy registry and on disparities by race and ethnicity.
Ransomware Attacks: The State Of Play As Indian Firms Mount Defense
Pharma continues to be targeted by cyber criminals – the latest being India’s top-ranked company, Sun Pharma. Experts highlight some of the key vulnerabilities and why firms need to prioritize cyber resilience.
- Generic Drugs
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Aditya Acquisition Company ltd
- Caraco Pharmaceutical Laboratories, Ltd.
- Concert Pharmaceuticals, Inc.
- DUSA Pharmaceuticals, Inc.
- InSite Vision, Inc.
- JSC Biosintez
- Ocular Technologies
- Pola Pharma Inc.
- Ranbaxy Laboratories Limited
- Ranbaxy Solus
- Solus Care
- Sun Ophthalmics
- Sun Pharma Global FZE
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.